Haemoglobin-based red cell substitutes have recently passed a myriad of safety studies and are now undergoing efficacy evaluation. There are numerous potential benefits with use of these solutions: they are readily available and have a long shelf-life; do not require typing and cross-matching; are free of viral or bacterial contamination; lack the immunosuppressive effects of blood; and have a much lower viscosity than blood. One-third of the 10 million units of blood transfused in the United States each year is utilized in the emergency setting. Therefore, a safe, effective substitute for blood should have significant impact upon the way we resuscitate bleeding patients. In this article, the current status of the various haemoglobin-based red cell substitutes is reviewed.
No takes yet. Share an insight, caveat, or question.
Stephen M. Cohn (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: